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SUMMARY 20 
Cellular immunity plays a relevant role in control of HSV-1 infection/reactivation with a potential 21 
impact on clinical-therapeutic management of immunocompromised patients, such as transplant 22 
recipients.  23 
Herein, we quantitatively evaluated T-cell response directed at HSV-1 by a newly developed IFN-γ 24 
EliSPOT assay in 53 patients (including 45 lung transplant recipients and eight subjects in waiting 25 
list). 26 
Overall, 62.2% of transplant patients and 62.5% of subjects in waiting list evidenced a response to 27 
HSV-1 with no significant difference in the level of virus-specific cellular immunity. Response 28 
tended to be lower in the first 3 months posttransplantation with progressive recovery of 29 
pretransplantation status by the second year and in the presence of HSV-1 DNA positivity in 30 
bronchoalveolar lavage. As expected, no response was found in seronegative patients. No 31 
significant difference in the level of response according to IgM and IgG status was found. 32 
Further studies are required to define the role of HSV-1 specific immune response for the clinical-33 
therapeutic management of lung transplant patients and in other clinical settings and to define cut-34 
off levels discriminating between absence/low and strong response to be related to the risk of viral 35 
infection/reactivation. 36 
 37 
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Introduction 40 
Herpes simplex virus type-1 (HSV-1) is a highly seroprevalent and ubiquitously distributed dsDNA 41 
virus belonging to the Herpesviridae family, α-herpesvirinae subfamily. Primary infection usually 42 
occurs early in the childhood and is followed by a lifelong latent infection in neurons of central 43 
ganglia, from which reactivation may occur. Whereas asymptomatic mucosal shedding is common 44 
and HSV-1 has been isolated from the saliva of 1-5% of healthy subjects (Tsakris and Pitiriga 45 
2011), reactivation has been reported particularly in immunosuppressed and critical patients in 46 
which, beside classical presentation, visceral or disseminated disease can occur, including extensive 47 
mucocoutaneous involvement, hepatitis, meningoencephalitis, and pneumonitis (Tsakris and 48 
Pitiriga 2011; Simmoons-Smit et al. 2006; Costa et al. 2012c; Wilk et al. 2013; Preiser et al. 2003; 49 
Bonizzoli et  al. 2016). As regards the lower respiratory tract, HSV-1 has been reported in 16 up to 50 
32% of the cases (Bruynseels et al. 2003; van den Brink et al. 2004; Daubin et al. 2005; Luyt et al. 51 
2007; Linssen et al. 2008) and has been increasingly associated to pulmonary diseases, with poor 52 
outcome and high mortality rates (Costa et al. 2012c; Luyt et al. 2007; Linssen et al. 2008; Ong et 53 
al. 2004; Engelmann et al. 2007; Gooskens et al. 2007; De Vos et al. 2009; Bouza et al. 2011; 54 
Scheithauer et al. 2010). Adaptive immunity plays a pivotal role in uncomplicated recovery from 55 
HSV infection, as evidenced by severe complications observed in immunocompromised 56 
individuals, although the kinetics and specificity of HSV-specific T-cells during primary infection 57 
are poorly unknown (Ouwendijk et al. 2013). After resolution of acute infection, memory T-cells 58 
are detected at moderate levels in blood of immunocompetent subjects, with a poly-specific T-cell 59 
response directed at distinct HSV-1 tegument and capsid proteins (Jing et al. 2012; Moss et al. 60 
2012). Blood HSV-specific T-cells express high levels of cytolytic molecules and secrete IFN-γ 61 
upon antigenic recall (Ouwendijk et al. 2013); higher levels of IFN-γ production are associated with 62 
polyfunctionality of T-cells and better control of chronic viral infection (Merindol et al. 2012; 63 
Harari et al. 2006). Moreover, HSV-1-specific T-cells localize to sites of primary and recurrent 64 
infections, as well as latency sites, contributing to control viral latency and reactivation (Ouwendijk 65 
et al. 2013; Khanna et al. 2003; Gebhardt et al. 2009; Ariotti et al. 2012). Quantitative evaluation of 66 
HSV-1-specific T-cell response in blood compartment and the study of the relation between this and 67 
ability of controlling local reactivation in the lung could be relevant for the clinical management of 68 
immunocompromised patients at risk of severe pulmonary complications. At moment, no assay for 69 
evaluation of cellular immune response to HSV-1 is available, as well as no data on its potential 70 
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impact on clinical/therapeutic management of infection/reactivation in different categories of 71 
patients have been evaluated. 72 
In the present study, we quantitatively evaluated T-cell responses directed at HSV-1 by an newly 73 
developed IFN-γ EliSPOT assay in a susceptible population such as lung transplant recipients and 74 
investigated the role of systemic virus-specific immunity in determining the risk of viral 75 
reactivation in the lower respiratory tract.  76 
 77 
78 
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Materials and methods 79 
Subjects and specimens 80 
Cellular immune response  to HSV-1 was evaluated in an observational, longitudinal and 81 
prospective study by IFN-γ EliSPOT assay on peripheral blood mononuclear cell (PBMC) 82 
specimens from all  lung transplant recipients admitted to the University Hospital “Città della Salute 83 
e della Scienza di Torino”, Turin, Italy (Regione Piemonte Transplant Centre) over a two-year 84 
period. The Lung Transplant Centre of the Piemonte region is the first in Italy for activity volume. 85 
Overall, 53 patients (M/F, 33/12; mean age ± standard deviation, 47.8 ± 15.2 years; range, 16-69), 86 
including  45 lung transplant recipients in the first two years posttransplantation and eight subjects 87 
in waiting list were prospectively evaluated. In this study population, one (in subjects in waiting 88 
list) or at least three (in transplant patients) PBMC specimens were collected, accounting for an 89 
overall number of  168 samples (160 from transplant recipients, including 81 from 27 patients with 90 
three evaluations, 64 from 16 patients with four evaluations, and 15 from three patients with five 91 
evaluations; eight specimens from individuals in waiting list). A pre-transplant evaluation of HSV-1 92 
cellular immune response was also obtained for all the patients, but three. Pretransplant serological 93 
data for HSV-1/2 (IgG and IgM serostatus) were extrapolated from the local Transplant Registry 94 
and were available for all patients, in particular five individuals IgG-negative and 48 IgG–positive, 95 
with five subjects being IgM-positive. Baseline characteristics of the enrolled patients are reported 96 
in Table 1. Moreover, 42 healthy seropositive individuals (IgG-positive, IgM-negative),  including 97 
38 without recurrent HSV-1 infection and four with at least one episode of HSV-1 infection (herpes 98 
labialis) in the previous 12 months, were also studied by a single EliSPOT determination. 99 
All subjects provided written informed consent and the study was approved by the institutional 100 
review board. According to our lung transplant center’s practice, all patients received prophylaxis 101 
for HSV consisting in administration of acyclovir (400 mg twice daily; to be reduced in case of 102 
kidney failure or suspended  in case of ganciclovir or valganciclovir treatment for CMV). In 103 
addition, all patients received a universal, prolonged and combined anti-viral prophylaxis for CMV, 104 
irrespective of serological matching donor/recipient, consisting in the administration of ganciclovir 105 
or valganciclovir (450 mg twice daily) from day 21 posttransplantation for 3 weeks associated to 106 
CMV-Ig (Cytotect Biotest) at days 1, 4, 8, 15, and 30 (1.5 ml/kg body weight) and monthly up to 2 107 
years posttransplantation, according to local practice. Long-term immunosuppression was 108 
maintained with tacrolimus or cyclosporine A (in patients with cystic fibrosis as underlying 109 
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disease), mycophenolate mofetil and prednisone (to be tapered or discontinued). Follow-up 110 
surveillance bronchoscopies (with bronchoalveolar lavage [BAL] and transbronchial biopsy) were 111 
scheduled at 1, 3, 6, 9, 12, 18, and 24 months posttransplantation, for the evaluation of rejection and 112 
infections in the lower respiratory tract, as previously described (Costa et al. 2012a; Costa et al. 113 
2008; Costa et al. 2011; Costa et al. 2012b). Therefore, virological data for HSV-1 were available 114 
on BAL specimens concomitantly collected with samples for EliSPOT assay in all the cases. HSV-1 115 
was evaluated on BAL specimens by real-time PCR using a commercially available kit (HSV-1 116 
ELITe MGB® kit, ELITechGroup) following automated extraction with the Qiasymphony (Qiagen, 117 
Hilden, Germany) instrument. Rapid shell vial isolation with indirect immunofluorescence for 118 
HSV-1 was also performed, as previously described (Costa et al. 2007).  119 
 120 
IFN-γ EliSPOT assay   121 
HSV-1 antigenic stimulus consisted of a freeze-thaw/sonicated viral lysate prepared from expanded 122 
long-term cultures of Vero cells (kidney epithelial cells from African green monkey, as previously 123 
described (Terlizzi et al. 2009), infected with the Human herpesvirus 1 ATCC® VR-260TM 124 
[American Type Culture Collection, Manassas, VA, USA]). Aliquots of viral preparation were 125 
stored at -80°C until use. For virus titration, 96-well plates at 60-80% confluence of Vero cells were 126 
inoculated with 100 µl of 10-fold diluted virus for TCID50 assay, obtaining an end-point titer of 127 
3.16 x 108 TCID50/ml. Sonication included thawing of the virus in ice and 3 cycles at 20% intensity 128 
for 30 seconds using the Sonopuls Ultraschall-Homogenisatoren instrument (Bandelin electronic 129 
GmbH, Berlin, Germany). Subsequently, the virus underwent a through UV irradiation for 130 
inactivation, with two cycles per transilluminator set at 1.2 J/cm2. UV inactivation was carried out 131 
also on the RPMI 1640-medium (Sigma-Aldrich, St. Louis, MO, USA), used for the EliSPOT assay 132 
(see below). In order to ascertain the effective inactivation of the virus, a rapid shell vial culture 133 
assay followed by indirect immunofluorescence was performed, as previously described (Costa et 134 
al. 2007), and resulted negative (Figure 1). For antigenic stimulus, serial dilutions from 106 up to 135 
103 of the inactivated virus, starting at 3.16 x 108 TCID50/ml were used. Dose response curves were 136 
performed with the lysate preparation to determine the amount of antigenic stimulus to use in the 137 
IFN-γ EliSPOT assay: in particular, on PBMCs obtained from four healthy controls and two lung 138 
transplant recipients. 139 
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Whole blood was collected directly into CPT Vacutainer tubes (BD, Franklin Lakes, NJ, USA) and 140 
PBMCs were separated by density gradient sedimentation according to manufacturer instructions, 141 
with minor modifications. Briefly, blood samples were centrifuged at 1800 g for 20 min at room 142 
temperature. The resulting mononuclear cell fraction was washed twice with phosphate buffered 143 
saline (PBS 1x, pH 7.4). Resulting PBMCs were cryopreserved in fetal calf serum (PAA 144 
Laboratories GmbH, Pasching, Austria) with 10% dimethyl sulfoxide, placed into Nalgene 145 
Cryovials (Nalge Nunc, Rochester, NY, USA) at -80°C for ≥24 h prior to transfer to liquid nitrogen 146 
for long-term storage.  147 
The IFN-γ EliSPOT assay was performed as described elsewhere (Costa et al. 2012b). Briefly, 148 
PBMCs were thawed in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% 149 
fetal calf serum and 1% l-glutamine, washed twice and rested for at least 4 h in complete RPMI-150 
1640 at 37°C, 5% CO2, before assay. Subsequently, cell viability and count were assessed by trypan 151 
blue staining in Burker’s chamber to a final concentration of 2 x 106 cells/ml. Peripheral blood 152 
mononuclear cells were plated at 2 x 105 cells/well onto a 96-well microplate pre-coated with anti-153 
human IFN-γ monoclonal antibody (EliSPOT Interferon-γ Basis Kit; AID, Strassberg, Germany) 154 
and incubated with viral preparations, as described above. For negative and positive controls, cells 155 
incubated with supplemented RPMI -1640 medium alone and with 1 µg/ml phytohemagglutinin 156 
mitogen (supplied by ELITechGroup, Milan, Italy) were used, respectively. Following a 18-20 h 157 
incubation at 37°C, 5% CO2, the microplates were washed 8-times with washing buffer and 158 
incubated with biotinylated anti-human IFN-γ mAb at 1 µg/ml in VP buffer at room temperature in 159 
a wet chamber, in the dark, for 2 h. Subsequently, the microplates were washed 8-times with 160 
washing buffer and incubated with streptavidin-horseradish peroxidase solution diluted 1:1000 in 161 
blocking buffer. Following another washing step, as before, substrate solution 162 
(tetramethylbenzidine) was added for colour development at room temperature in the dark for 12-15 163 
min. The chromogenic reaction was stopped by extensive washing with tap water and microplates 164 
were allowed to completely dry before analysis. Results were analyzed using a computer-assisted 165 
system (AID EliSPOT Reader System, AID). Data were expressed as spot-forming units (SFU)/2 x 166 
105 cells, with each spot representing a single cell that produces IFN-γ, calculated by subtracting the 167 
mean of SFU obtained in unstimulated negative control from the mean SFU obtained in the antigen-168 
stimulated wells.  169 
Statistical analysis 170 
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For descriptive statistics, data were expressed as raw number and percentage. For statistical 171 
analysis, chi square, t test, and analysis of variance (ANOVA, followed by Bonferroni post-test) 172 
were applied, as appropriate. A p value <0.05 was considered significant. Statistical analysis was 173 
performed using GraphPad Prism version 5 (GraphPad Software, San Diego, USA). 174 
 175 
176 
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Results 177 
Validation of the EliSPOT assay 178 
Based on dose-response curves on preliminary EliSPOT assays performed in triplicate on PBMCs 179 
from four IgG positive healthy controls and two IgG-positive lung transplant patients, serial HSV-1 180 
lysate dilutions at 3.16 x 104 and 3.16 x 103 TCID50/mL were associated to more robust and 181 
reproducible responses, even though not at statistical level (p = n.s.)(Figure 2). Therefore, these 182 
dilutions were used as antigenic stimuli for subsequent HSV1-EliSPOT evaluations on specimens 183 
from study population. The results evidenced that 3.16 x 103 TCID50/mL HSV-1 stimulus was 184 
associated to higher responses in comparison to 3.16 x 104 TCID50/mL (mean SFU/2 x 10
5 PBMCs 185 
± SD;  3.765 ± 5.516 versus 2.662 ± 4.531, p=0.048), when considering samples from 186 
posttransplantation setting (peak value of response for each patient)(Figure 3).  187 
 188 
Clinical evaluation 189 
Overall, 28/45 (62.2%) transplant patients and 5/8 (62.5%) patients in waiting list evidenced a 190 
positive response to HSV-1 lysate, with level of response ranging from 1 to 211 and from 8 to 53 191 
SFU/2 x 105 PBMCs, respectively. No significant difference of response was found between 192 
samples from pre- and post-transplant patients, considering both all specimens (mean SFU/2 x 105 193 
PBMCs ± SD, 8.9 ± 15.9 versus 7.2 ± 25.6; p = 0.870) and specimens with peak value from each 194 
patient (10.4 ± 18.1 versus 5.15 ± 25.6; p = 0.120). Subsequently, as the main risk of HSV-1 195 
infection is in the first period posttransplantation (up to 3 months, particularly the first 30 days), we 196 
compared the degree of specific cellular response in specimens collected in the first 3 months 197 
(overall, 10 specimens from as many patients) versus those collected at > 3 months and found no 198 
significant differences, although mean values of SFU/2 x 105 PBMCs tended to be lower in the early 199 
period in comparison to >3 months (mean ± SD, 2.7 ± 5.5 versus 7.4 ± 27.3; p = 0.638). 200 
Among healthy seropositive individuals, 39/42 (83.3%) evidenced a positive response to HSV-1 201 
lysate (37 with no episode of  recent HSV-1 infection in the previous 12 months, two with two 202 
episodes of herpes labialis), with level of response ranging from 8 to 36 SFU/2 x 105 PBMCs; in 203 
three subjects no response was found (one with no episode of HSV-1 infection and two with an 204 
episode of herpes labialis in the previous 12 months). No significant difference of response was 205 
found between individuals with and without HSV-1 infection.  206 
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Considering serostatus, as expected, no response was found in seronegative patients, whereas a 207 
mean level of 11.2 SFU/2X105 PBMCs (range, 0-211; median, 3) was found in seropositive 208 
patients, with no significant difference in IgM-positive versus IgM-negative patients (mean SFU/2 x 209 
105 PBMCs ± SD, 3.5 ± 4.7 versus 11.6 ± 33.6; p = 0.585). In Table 2, HSV-1 responses to different 210 
antigenic concentrations according to IgG serostatus are reported.  211 
In order to investigate the kinetics of HSV-1-specific T-cell immunity after lung transplantation, 212 
EliSPOT data were evaluated at different time points, including prior to transplantation, at 1 month 213 
and at 6-month intervals posttransplantation. The pattern of HSV-1 specific cellular immune 214 
response evidenced a decrease in the first months posttransplantation in comparison to 215 
pretransplantation levels; this was seen with both 3.16 x 103 and 3.16 x 104 TCID50/mL antigenic 216 
stimuli (mean SFU/2 x 105 PBMC ± SD, 2.889 ± 5.061 versus 9.5 ± 16.10, and 1.0 ± 2.0 versus 8.2 217 
±15.30, respectively), with progressive recovery of pretransplantation levels at the end of the 218 
second year posttransplantation (5.444 ± 8.819 versus 4.222 ± 6.685, for 3.16 x 103 and 3.16 x 104 219 
TCID50/mL HSV-1 stimuli, respectively)(Figure 4, A and B). This kinetics was observed also when 220 
excluding patients with HSV-1 DNA positivity on BAL specimens in concomitance with the 221 
EliSPOT determinations (n=7)(Figure 4, C and D). 222 
Seven lung transplant recipients (15.6%) exhibited at least one episode of HSV-1 lower respiratory 223 
tract infection (as determined by molecular detection of HSV-1 DNA on BAL specimens [Costa et 224 
al. 2012c]), concomitant to the available EliSPOT assays. All cases of HSV-1 infection occurred in 225 
IgG-positive recipients, likely due to viral reactivation. In these patients, the level of HSV-1 cellular 226 
immunity tended to be lower in comparison to patients with no HSV-1 DNA positivity, even though 227 
not reaching statistical significance (mean EliSPOT values: 1.143 ± 0.5533 versus 3.967 ±0.7295; 228 
p=0.1986). 229 
In order to assess the impact of pulmonary events of HSV-1 replication on subsequent virus-specific 230 
immunity induction, BAL determinations performed in a 6-month period prior to the available 231 
EliSPOT assays were retrospectively investigated. Six patients exhibited a history of at least one 232 
episode of pulmonary HSV-1 replication in this period; in these patients, HSV-1 EliSPOT response 233 
tended to be higher in comparison to patients with no evidence of lower respiratory tract infection in 234 
the same interval (mean SFU/2 x 105 PBMC, 8.167 ± 3.229 versus 3.568 ± 0.7953, p=0.0656, using 235 
3.16x103 TCID50/mL as antigenic stimulus). Moreover, no relation was found between HSV-1 236 
EliSPOT responses and the occurrence of HSV-1 positivity in the subsequent 6-month period.237 
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Discussion 238 
In this study, cellular immune response to HSV-1 was evaluated by a newly developed IFN-γ 239 
EliSPOT assay. Whereas Posavad and colleagues described an EliSPOT assay for HSV-2 to be used 240 
in vaccine development (Posavad et al. 2011), an assay specifically designed for HSV-1 has not 241 
been reported in literature and its availability could be useful for defining the role of cellular 242 
immunity in the development and outcome of HSV-1 infection/reactivation, as well as in its clinical 243 
and therapeutic management. Immunocompromised patients, such as transplant recipients, present 244 
more frequent and severe clinical manifestations of HSV-1 infection, as well as decreased responses 245 
to anti-viral treatment (Wilk et al. 2013). In most of the cases, symptomatic HSV-1 disease in adult 246 
transplant recipients results from viral reactivation, particularly in the first month following 247 
transplantation (Fishman 2007). Among other clinical manifestations, including disseminated 248 
mucocutaneous disease, esophagitis and hepatitis, pneumonitis is described in all solid organ 249 
transplant patients, but most commonly in lung and heart-lung transplant patients (Smyth et al. 250 
1990). The kinetics and specificity of HSV-1 T-cell immune response during primary infection are 251 
poorly known in humans. Following resolution of acute episode, specific memory T-cells are found 252 
at moderate levels of 0.1-1% in immunocompetent individuals (Ouwendijk et al. 2013; Jing et al. 253 
2012; Moss et al. 2012). In healthy individuals, a complex and poly-specific CD4+ and CD8+ 254 
response towards more than 70 different proteins has been identified, including proteins abundantly 255 
present in the virion (e.g. viral envelope, tegument, capsid) and regulatory proteins (Jing et al. 2012; 256 
Merindol et al. 2012; Harari et al. 2006; Jing et al. 2013). HSV-1 specific T-cells localize to sites of 257 
primary, recurrent and chronic latent infections from which reactivation may occur in favoring 258 
conditions, such as immunosuppression. Several studies have demonstrated that the outcome of 259 
these infections depends on the efficacy of specific cellular immune response (Remakus and Sigal 260 
2013; Sant and McMichael 2012; Calarota et al. 2015) and that the development of quantitative, 261 
sensitive and reproducible assays for evaluation and monitoring of virus-specific T-cell response is 262 
fundamental to investigate kinetics of HSV-1-specific immunity and in the clinical-therapeutic 263 
management of immunocompromised patients. 264 
Among methods developed for evaluating virus-specific T-cell response, the  EliSPOT assay allows 265 
for measurement of quantity and functionality of specific T-cells and can be used to define the 266 
whole repertoire of cellular responses without MHC-restriction. EliSPOT assay detects production 267 
of IFN-γ by PBMCs following stimulation with specific antigens and enumerates responsive cells 268 
using anti-IFN-γ monoclonal antibodies coated onto 96-well plates and a second enzyme-269 
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conjugated monoclonal antibody; spots are counted using automated EliSPOT readers with each 270 
spot representing a single specific cell (Calarota et al. 2015).The most common antigenic stimuli 271 
used for EliSPOT assay are pools of overlapping peptides, peptide libraries spanning entire proteins 272 
or viral lysates. Given the antigenic complexity of herpesviruses which contain multiple potential 273 
protein targets recognized by CD4+ cells and the dose-response curves obtained on preliminary 274 
EliSPOT assays, in this study a viral lysate preparation at 3.16 x 104 and 3.16 x 103 TCID50/mL 275 
dilutions was used. 276 
By using these two dilutions of inactivated virus, we found that 3.16 x 103 TCID50/mL HSV-1 277 
stimulus was significantly associated to higher level of response in comparison to 3.16 x 104 278 
TCID50/mL. This difference was evidenced in almost all cases with very few exceptions and 279 
considering those collected in both the pre- and post-transplant settings; it could be hypothesized 280 
that this is due to the degree of saturation of binding sites.  281 
As regards HSV-1 specific cellular immune response in study population, there was no significant 282 
difference in its level between the pre- and post- transplant period. As the higher risk (Fishman 283 
2007) of HSV-1 reactivation is in the very first months (particularly up to 30 days), we evaluated 284 
whether this could be attributable, at least partly, to a lower degree of virus-specific cellular 285 
immune control. Although the difference was not significant, a tendency to lower levels of response 286 
in the first period was found; of course, it should be taken into account the small number of 287 
specimens that could have limited the statistical power of these data and the need for increasing the 288 
study group.  Moreover, it has to be underlined that we consider cumulative data from all the 289 
specimens available for a certain period of time posttransplantation, giving the differne tnumebr of 290 
samples available at different time points. 291 
Knowledge of HSV-1 serostatus, as well as of cell-mediated immune response, may be of great 292 
concern to stratify patients at major risk for primary HSV-1 acquisition – either from the allograft or 293 
from natural sources – after transplantation, which may be more clinically severe and prolonged due 294 
to lack of immunologic memory (Wilck and Zuckerman 2013; Nichols et al. 2003). As expected, no 295 
response was found in seronegative patients; on the other side, when considering seropositive 296 
patients, no significant difference in the degree of virus-specific response was found between IgG- 297 
and IgM-positive individuals, although values tended to be higher in patients with a serological 298 
status suggesting previous infection. This observation supports the hypothesis that a higher level of 299 
response is achieved following immunological boosting of memory T-cell, as already reported for 300 
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cytomegalovirus (Costa et al. 2014a; Rittà et al. 2015; Abate et al. 2010), Epstein-Barr virus (Rittà 301 
et al. 2015) and polyomavirus BK (Costa et al. 2014b).   302 
Given the occurrence of HSV-1 infection/reactivation in the lower respiratory tract and the potential 303 
impact in the presence of impaired immune responses, as reported for other herpesviruses (Costa et 304 
al. 2007), a study population of lung transplant recipients was chosen for clinical validation of the 305 
developed HSV-1 EliSPOT assay and evaluation of kinetics of specific cellular immune response. 306 
As expected, a decrease (although not significant) in the level of response in the first months 307 
posttransplantation was found in comparison to pretransplantation levels, with progressive recovery 308 
of these levels along a period ranging from 3 months to 2 years posttransplantation.  309 
As regards HSV-1 infection in the lower respiratory tract, as evidenced by positivity to HSV-1 310 
DNA on BAL specimens, all the cases occurred in IgG-positive patients, thus representing viral 311 
reactivation. In terms of impact of the level of HSV-1 specific cellular immune response on viral 312 
reactivation, although not statistically significant, a tendency to lower levels in the seven patients 313 
with at least one episode of infection  was observed, with values even lower in the presence of 314 
repeated episodes. Moreover, as these data referred to concomitant evaluation of HSV-1 DNA on 315 
BAL and EliSPOT assay, we also assessed the impact of pulmonary HSV-1 infection on subsequent 316 
level of virus-specific cellular immune response by retrospectively investigating BAL 317 
determinations in a 6-month period prior to the available EliSPOT assay. Interestingly, in patients 318 
with at least one episode of pulmonary HSV-1 infection in comparison to those with no infection, 319 
the degree of cellular immune response tended to be higher, thus supporting the boosting effect of 320 
viral replication on the development of HSV1-specific immunity. 321 
In conclusion, we have evaluated T-cell responses directed at a HSV-1 in lung transplant patients by 322 
a newly developed, specific and quantitative IFN-γ EliSPOT assay and investigated the 323 
immunological status and kinetics. The availability of this assay could allow for a patient’s tailored 324 
clinical-therapeutic management in terms of modulation of immunosuppressive therapy and use of 325 
antiviral agents in the presence of HSV-1 infection/reactivation in relation to the occurrence and 326 
level of virus-specific response. Further studies on larger and different populations of 327 
immunocompromised and immunocompetent patients are required to define the potential of 328 
quantitative evaluation of HSV-1 specific cellular immune response in different clinical settings and 329 
to define cut-off levels discriminating between absence/low and strong response to be related to the 330 
risk of viral infection/reactivation. 331 
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Table 1.  Demographic and clinical features of study population. BAL, bronchoalveolar lavage; 463 
COPD, chronic obstructive pulmonary disease; CSA, cyclosporin A; MMF, mycophenolate mofetil; 464 
MPA, mycophenolic acid; TAC, tacrolimus; AZA, azathioprine; EVR, everolimus. Details on 465 
antiviral prophylaxis are reported in the text. 466 
Features  
Patients, total n  
  Male/female, n 
  Mean age (range), years 
95 
  56/39 
  47.2 (16-69) 
Healthy seropositive individuals, n 
  Mean age (range), years 
  N. of EliSPOT determinations per patient  
42 
 37.5 (21-49) 
 1 
Pre-transplant patients, n 
  Mean age (range), years 
  N. of EliSPOT determinations per patient    
8 
 47 (22-65) 
 1 
Post-transplant patients, n 
  Mean age (range), years 
  N. of EliSPOT determinations per patient   
     (mean, range) 
  Time of EliSPOT determinations post-transplantation   
    (months – mean, range) 
45 
  47.0 (16-69) 
  3.6 (3-5) 
 
  21 (1-94) 
Type of lung transplant  
  Monolateral 
  Bilateral 
 
9 
36 
Underlying disease 
  Cystic fibrosis 
  COPD/emphysema 
  Idiopathic pulmonary fibrosis 
  Bronchiectasis 
  Extrinsic allergic alveolitis 
 
37 (50.7%) 
22 (26.0%) 
  6 (8.2%) 
  7 (9.6%) 
  1 (1.4%) 
Antiviral prophylaxis (in all transplant patients) 
  HSV  
 CMV 
 
Acyclovir 
Ganciclovir or 
valganciclovir + 
CMV-Ig  
Immunosuppressive regimens 
  CSA + MMF 
  CSA + MPA 
  TAC + MMF 
  TAC + MPA 
  TAC + AZA 
  TAC + EVR 
 
25 
1 
15 
2 
1 
1 
HSV-1/2 serology at baseline 
  IgM+ 
  IgM- 
  IgG+ 
  IgG- 
 
5 
48 
48 
5 
 467 
 468 
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Table 2. HSV-1 EliSPOT responses to different antigenic concentration according to IgG serostatus 469 
(mean ± standard deviation,  spot forming units [SFU]/2x105 peripheral blood mononuclear cells 470 
[PBMCs]).  471 
 HSV IgG+ 
(n = 48) 
HSV IgG- 
(n = 5) 
p  
3.16x103 TCID50/mL 5.447 ± 1.543 0.2 ± 0.2 0.24 
3.16x104 TCID50/mL 3.929 ± 1.335 0.2 ± 0.2 0.32 
 472 
473 
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Figure 1. Rapid shell vial culture assay with indirect immunofluorescence using Vero cells infected 474 
with (A) human Herpesvirus 1 ATCC® VR-260TM, (B) UV-inactivated HSV-1 preparation 475 
(dilution 3.16 x 108 TCID50/mL), and (C) UV-treated RPMI-1640 complete medium alone at 24 h 476 
post-infection (Fluorescein isothiocyanate; counterstaining with Evans blue 1:10000). 477 
Magnification, 25X. 478 
 479 
Figure 2.  EliSPOT assay on peripheral blood mononuclear cells from a HSV-1 IgG-positive lung 480 
transplant patient stimulated with serial dilution of UV-inactivated HSV-1 preparation: (A) 3.16 x 481 
104 TCID50/mL, (B) 3.16 x 103 TCID50/mL, (C) RPMI-1640 complete medium alone, and (D) 482 
phytohemagglutinin mitogen (PHA) 1 µg/mL. Results are reported as spot forming unit 483 
(SFU)/2x105 cells.   484 
 485 
Figure 3. HSV-1 EliSPOT responses according to concentrations of HSV-1 antigenic stimulus in 486 
samples from posttransplantation patients (peak value of response for each patient). 487 
 488 
Figure 4. Kinetics of HSV-1 EliSPOT responses according to concentrations of HSV-1 antigenic 489 
stimulus considering all specimens from transplant patients (A, 3.16 x 103 TCID50/mL; B, 3.16 x 490 
104 TCID50/mL) and excluding specimens from patients with concomitant HSV-1 positivity on 491 
bronchoalveolar lavage (BAL) (C,  3.16 x 103; D, 3.16 x 104 TCID50/mL). Determinations are 492 
grouped as follows: at pre-transplant (n = 42), up to 1month (n = 7), at 1-6 months (n = 13), at 6-12 493 
months (n = 79), at 12-18 months (n = 53), and at 18-24 months (n = 8) post-lung transplantation 494 
(LT). 495 
